Relationship between Target Lesion Revascularization after PCI and Serum Cholesterol levels, and Influence of HMG-CoA Reductase Inhibitors in This Respect

Elevated cholesterol levels are a primary risk factor for the development of coronary artery disease. Dietary changes associated with drug therapy can reduce high serum cholesterol levels and dramatically decrease the risk of stroke and overall mortality. HMG- CoA reductase is an important molecular target of hypolipemic drugs, known as statins, which are effective in the reduction of cholesterol serum levels, attenuating cholesterol synthesis in-liver by competitive inhibition regarding the substrate HMG- CoA . In this paper, we have focused on computer-aided molecular design using density functional theory, flexible docking, molecular dynamics as well as ADME, and synthetic accessibility analyses in order to propose novel potential HMG- CoA reductase inhibitors, designed by bioisosteric modifications which are promising for the treatment of hypercholesterolemia.

Download Full-text

Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease

Current Alzheimer Research ◽

10.2174/156720511795745393 ◽

2011 ◽

Vol 8 (4) ◽

pp. 434-442 ◽

Cited By ~ 14

Author(s):

Justin Longenberger ◽

Zahoor A. Shah

Keyword(s):

Alzheimers Disease ◽

Hmg Coa Reductase ◽

Brain Cholesterol ◽

Reductase Inhibitors ◽

Cholesterol Levels ◽

Hmg Coa Reductase Inhibitors ◽

Coa Reductase

Download Full-text

HMG-CoA reductase inhibitors - their role in the fight against elevated cholesterol levels

InPharma ◽

10.1007/bf03308715 ◽

1988 ◽

Vol 648 (1) ◽

pp. 17-18

Keyword(s):

Hmg Coa Reductase ◽

Reductase Inhibitors ◽

Cholesterol Levels ◽

Elevated Cholesterol ◽

Hmg Coa Reductase Inhibitors ◽

Coa Reductase

Download Full-text

Prevention and Regression of Atherosclerosis: Effects of Hmg-CoA Reductase Inhibitors

Annals of Pharmacotherapy ◽

10.1177/106002809603001116 ◽

1996 ◽

Vol 30 (11) ◽

pp. 1304-1315 ◽

Cited By ~ 3

Author(s):

Aleksandra Bjelajac ◽

Alvin KY Goo ◽

C Wayne Weart

Keyword(s):

Serum Cholesterol ◽

Carotid Atherosclerosis ◽

Density Lipoprotein ◽

Atherosclerotic Disease ◽

Lipid Lowering ◽

Cardiac Events ◽

Hmg Coa Reductase ◽

Reductase Inhibitors ◽

Hmg Coa Reductase Inhibitors ◽

Coa Reductase

OBJECTIVE: TO review the current literature on the effects of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors in secondary prevention and regression of atherosclerosis. DATA SOURCES A MEDLINE and journal search of recent studies evaluating the effects of lipid lowering with HMG-CoA reductase inhibitors on serum cholesterol as well as progression and regression of atherosclerotic coronary or carotid disease in patients with established atherosclerotic disease was conducted. Articles addressing the pathophysiology of atherosclerotic disease were identified by using the same sources. STUDY SELECTION: All available studies evaluating the use of HMG-CoA reductase inhibitors in the progression and regression of coronary and carotid atherosclerosis were reviewed. DATA SYNTHESIS: Lowering of total serum cholesterol, low-density lipoprotein cholesterol, and triglycerides, as well as increasing high-density lipoprotein cholesterol can be achieved with HMG-CoA reductase inhibitors. Aggressive lipid lowering has been demonstrated to alter progression of established atherosclerotic disease and, in some patients, actually induce regression of the atheroma. An unexpected finding of several trials was the early and significant reduction in clinical cardiac events. Other mechanisms by which clinical event reduction may be explained include plaque stabilization and restoration of endothelium vasodilation. CONCLUSIONS: Aggressive lipid-lowering therapy using HMG-CoA reductase inhibitors appears to alter the natural progression and promote regression of atherosclerosis in selected patients with established coronary or carotid atherosclerosis. However, it is unlikely that regression of atherosclerosis alone is responsible for the marked reduction in clinical cardiac events seen in these trials.

Download Full-text